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Protease-activated receptors (PARs) form a small family of G
protein-coupled receptors (GPCRs) mediating responses of cells
to extracellular proteases [1]. PAR1, the prototypical receptor of
this family, is a predominant mediator of thrombin signaling in
many cell types, including human platelets, endothelial cells, ﬁbro-
blasts and smooth muscle cells [1]. The activation of PAR1 by
thrombin occurs through the irreversible cleavage between Arg41
and Ser42 in the extracellular N terminus of the receptor. The trun-
cated N terminus forms a new domain, binds intra-molecularly and
acts as a tethered ligand triggering transmembrane signaling [2].
Proteolytic activation of PAR1 by thrombin also results in the
release of a peptide with a potential length of 41 amino acids,
namely parstatin. Strikingly, it was recently shown that parstatin
mediates signiﬁcant biological effects. The peptide efﬁciently
blocked angiogenesis in several in vivo, ex vivo and in vitro studies
[3]. In established animal models used for evaluation of neovascu-
lar ocular diseases, parstatin was found to prevent corneal, choroi-
dal and retinal neovascularization without obvious side effects [4].
Parstatin also exhibited vasodilatory properties and was effectivechemical Societies. Published by E
. Tsopanoglou), schuelein@in cardioprotection during ischemia and reperfusion injury. Parst-
atin treatment before, during or after ischemia signiﬁcantly de-
creased infarct size in an in vivo model of myocardial ischemia–
reperfusion injury [5]. Although parstatin has attractive properties
which may be transformed into therapeutic application in the fu-
ture, several key questions regarding its sequence and structure
are unclear. Most importantly, the precise length of the peptide
is still unknown despite some attempts to detect and identify it
in cell supernatants [6,7]. While it is clear that the peptide is re-
leased by cleavage between Arg41 and Ser42, its actual length de-
pends on whether the PAR1 possesses an N-terminal cleavable
signal peptide or not.
Cleavable signal peptides of GPCRs and other integralmembrane
proteins mediate integration of the proteins into the membrane of
the endoplasmic reticulum (ER), the initial step of the intracellular
transport. Most GPCRs do not possess cleavable signal peptides but
instead a non-cleaved signal anchor sequence which takes over sig-
naling functions (usually the ﬁrst transmembrane domain of the
mature receptor). Both types of signal sequences bind to the signal
recognition particle (SRP) and mediate targeting of the nascent
chains to the translocon complex at the ER membrane. The signal
sequences also facilitate opening of the Sec61 protein-conducting
channel of the translocon complex in order to integrate the nascent
chain into the bilayer. Whereas signal peptides are cleaved off fol-
lowing ER insertion by the signal peptidases of the ER, signal anchorlsevier B.V. All rights reserved.
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cently shown that even signal peptidesmay remain as an uncleaved
pseudo signal peptide at the N tail of a GPCR [8–10].
Here, we have addressed the question of whether the PAR1 pos-
sesses an N-terminal cleavable signal peptide or not. If a cleavable
signal peptide is present, the thrombin-released parstatin peptide
would only be 20 amino acids long. If not, the actual parstatin
length would be 41 amino acid residues. We show that the PAR1
possesses a functional and cleaved signal peptide resolving the
question of actual parstatin length. Moreover, we show that the
sequence encoding the signal peptide surprisingly plays a role in
stabilization of the PAR1 mRNA secondary structure.
2. Materials and methods
2.1. Materials
The PAR1 cDNA was purchased from the Missouri University of
Science and Technology (Rolla, MO, USA). The vector plasmid
pEGFP-N1 (encoding the enhanced green ﬂuorescent protein), the
ER marker plasmid pECFP-ER (encoding the enhanced cyan ﬂuores-
cent protein fused with a KDEL ER retrieval sequence), TALON me-
tal afﬁnity beads and the monoclonal mouse antibody against the
green ﬂuorescent protein (GFP) were from BD Biosciences Clontech
(Mountain View, CA, USA). The transfection reagent Lipofectamine
2000, Trizol reagent, SuperScript III First-Strand Synthesis Super-
Mix kit were from Invitrogen (Karlsruhe, Germany). DNA-modify-
ing enzymes and peptide-N-glycosidase F (PNGaseF) were from
New England Biolabs (Frankfurt am Main, Germany). Oligonucleo-
tides were purchased from Biotez (Berlin, Germany). Trypan blue
was purchased from Seromed (Berlin, Germany). RotiLoad sample
buffer was from Carl Roth (Karlsruhe, Germany). TMB (3, 30, 5, 50-
tetramethylbenzidine) was from Calbiochem (Darmstadt,
Germany). Polyclonal rabbit anti-GFP antiserum 02 (raised against
a GST-GFP fusion protein) has been described [10]. HRP-conjugated
goat anti-mouse IgG was purchased from from Dianova (Hamburg,
Germany). Monoclonal mouse anti-FLAG M2 antibody and mono-
clonal mouse peroxidase-conjugated anti-FLAG M2 antibody Acti-
nomycin D and all other reagents were from Sigma–Aldrich
(Taufkirchen, Germany).
2.2. Plasmid constructs
The constructs used in this study are schematically shown in
Fig. 1A. Marker protein fusions: plasmids pCRF1.NT and pCRF2(a).NT
encode C-terminal his tagged GFP fusions to N tail sequences of the
rat corticotropin-releasing factor receptor type 1 (CRF1R) and type
2(a) (CRF2(a)R) in the vector pSecTag2A plasmid, respectively
(CRF1R: fusion at position Ala119 predicted N tail length including
the signal peptide = 119 residues; CRF2(a)R: fusion at position
Ala121; predicted N tail length including the pseudo signal pep-
tide = 116 residues). The additional C-terminal His6-sequence at
the GFP moiety allowed the puriﬁcation of all GFP fusion proteins.
Plasmid pPAR1.NT was constructed by fusing C-terminally His-
Tagged GFP to an N tail sequence of the human PAR1 accordingly
(fusion at position Leu101; predicted N tail length including the
putative signal peptide = 101 residues). Full length receptor con-
structs: plasmids pCRF1 encodes the full length CRF1R C-terminally
fused with GFP (position Thr413) in the vector plasmid pEGFP-N1;
plasmid pDSP.CRF1 encodes the corresponding signal peptide
mutant (deletion of residues 1–24) [8]. Plasmid pPAR1 was con-
structed by fusing the full length PAR1 C-terminally with GFP
(position Thr425); plasmid DSP.PAR1 encodes the signal peptide
mutant of the latter construct (deletion of residues 1–21). Plasmids
pFLAG.CRF1 and pFLAG.PAR1 encode C-terminally GFP-tagged full
length receptors, possessing an additional N-terminal FLAG tag(sequence DYKDDDDK). Plasmid pFLAG.V2 encodes a C-terminally
GFP and N-terminally FLAG-tagged construct of the human vaso-
pressin V2 receptor (V2R).
2.3. Cell culture and transfection
HEK 293 cells were cultured at 37 C and 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% (v/v) fetal calf
serum (FCS), penicillin (100 U/ml) and streptomycin (100 lg/ml).
Transfection of the cells using Lipofectamine 2000 was carried
out according to the supplier’s recommendations. Equal amounts
of plasmid were transfected in each experiment.
2.4. Confocal laser scanning microscopy (LSM) and colocalization of
GFP and trypan blue or ECFP-ER ﬂuorescence signals in live cells
For colocalization of the GFP ﬂuorescence signals of the con-
structs with trypan blue, HEK 293 cells (2  105) grown on
poly-L-lysine-treated (25 lg/ml) glass coverslips in 35-mm diam-
eter dishes were transiently transfected with the plasmid DNA of
the constructs (1.2 lg). Cells were grown overnight, washed and
stained with trypan blue at ﬁnal concentration of 0.05% for
1 min. GFP and trypan blue ﬂuorescence signals were visualized
on a Zeiss LSM510-META invert confocal laser-scanning micro-
scope (objective lens: 100/1.3 oil; optical section:<0.8 lm; mul-
titrack mode; GFP, kexc: 488 nm, Argon laser, BP ﬁlter: 500–
530 nm; trypan blue, kexc: 543 nm, HeNe laser, LP ﬁlter:
560 nm). For colocalization of the GFP signals of the constructs
with those of the ER marker protein ECFP-ER, a cotransfection
was performed accordingly. GFP and ECFP-ER signals were visual-
ized on a Zeiss LSM780-META invert confocal laser-scanning
microscope (objective lens: 100/1.3 oil; optical section:<1 lm;
multitrack mode; GFP, kexc: 488 nm, Argon laser, BP ﬁlter:
496–534 nm; ECFP-ER, kexc: 458 nm, Argon laser, BP ﬁlter: 461–
500 nm).
2.5. Quantitative detection of secreted GFP fusion proteins
Secreted fusion proteins of transiently transfected HEK 293 cells
were puriﬁed and detected by SDS/PAGE immunoblotting as de-
scribed [8] using a monoclonal mouse anti-GFP antibody (dilution
1:3000) and HRP-conjugated anti-mouse IgG (dilution 1:5000).
GFP ﬂuorescence intensity of the secreted marker fusions was
quantiﬁed ﬂuorometrically as described [8] (kexc = 488 nm,
kem = 510 nm).
2.6. Immunoprecipitation of GFP-tagged full-length receptor
constructs
Full length receptor constructs of HEK 293 cells were precipi-
tated using the polyclonal anti-GFP antiserum 02 as described
[8]. Precipitated receptors were treated with PNGaseF prior to
immunoblot analysis according to the supplier’s recommenda-
tions. The GFP-tagged receptors were detected by SDS PAGE (10%
SDS, 48 cm2 gels) and immunoblotting using a monoclonal mouse
anti-GFP antibody (dilution 1:3000) and an HRP-conjugated anti-
mouse IgG (dilution 1:5000).
2.7. Cell surface ELISA assay
HEK 293 cells (20  103) grown in a 96 well plate pretreated
with 25 lg/ml poly-L-lysine were transiently transfected with plas-
mid DNA (200 ng/well) and cultivated for 24 h at 37 C. Cells were
washed two times with PBS (containing 0.5 mMMgCl2 and 0.5 mM
CaCl2) and ﬁxed for 15 min at room temperature (RT) using 4%
paraformaldehyde. Cells were washed three times with PBS and
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Fig. 1. (A) Schematic representation of the constructs used in this study. The signal peptides (SP) and the transmembrane domains are shown as black and gray boxes
respectively. N tail sequences are depicted as open boxes, FLAG tags are indicated by dark gray boxes. The numbers above each construct indicate the predicted number of
amino acid residues of the N tails (without signal peptide); the numerals below the constructs indicate predicted signal peptide length. Upper panel: marker protein fusions.
Fused GFP and His tags (H) are indicated. Lower panel: full-length receptor constructs. (B) Depiction of the N terminal sequence of the PAR1 including the putative signal
peptide (Met1–Ser21) and the sequence up to the thrombin cleavage site (Ala22–Arg41). The sequence Met1 to Arg41 was originally described as parstatin. For the signal
peptide, the probabilities of the presence of n (green), h (blue), and c (light blue) regions and the cleavage probabilities (cp, red) are indicated in a score ranging from 0 to 1.
D.E. Zampatis et al. / FEBS Letters 586 (2012) 2351–2359 2353treated with gelatine blocking reagent for 1h at RT. After washing
three times with ELISA buffer (PBS-buffer containing 0.05% Tween
20 and 0.5% BSA) monoclonal, peroxidase-conjugated anti-FLAG
M2 antibodies were added (1:2000 in ELISA buffer) and samples
were incubated for 1 h at 37 C. Cells were washed three times
with ELISA buffer and incubated with TMB for 30 min at RT in
the dark. The reaction was stopped by adding H2SO4 at a ﬁnal con-
centration of 0.5 N. Optical density (OD) at 450 nm was measured
(with correction at 630 nm to eliminate signals resulting from sur-
face impurities on the plates) using a Tecan Saﬁre multi-detection
monochrometer microplate reader (Männedorf, Switzerland). As-
say reliability was veriﬁed by blocking antibody binding using a
soluble FLAG epitope peptide.2.8. Immunoﬂuorescence microscopy
HEK 293 cells (1.5  105) grown in 24 well plates with cover
slips pretreated with 25 lg/ml poly-L-lysine were transiently
transfected with plasmid DNA (1.2 lg). Cells were cultured for
24 h, washed twice in serum free DMEM and incubated with a
monoclonal anti-FLAG M2 antibody (dilution 1:1000) for 1 h at
4 C. Cells were washed three times with PBS containing 0.5 mM
MgCl2 and 0.9 mM CaCl2 and then ﬁxed for 5 min at 4 C with 4%
(w/v) PFA. Cells were washed with PBS containing 1% non fat dry
milk and 150 mM sodium acetate (pH 7.0) and incubated for
15 min at RT in the same buffer without sodium acetate. Cells were
incubated with Cy3-conjugated goat anti-mouse IgG (dilution
2354 D.E. Zampatis et al. / FEBS Letters 586 (2012) 2351–23591:500) for 1 h at RT, washed and transferred to LSM analysis
(kexc = 488 nm, kem = 507 nm).
2.9. Total RNA extraction, cDNA synthesis, qRT PCR and mRNA
degradation assay
HEK 293 cells (4  106) were grown on 100 mm diameter dishes
and transiently transfected with plasmid DNA as described above.
RNA extraction was performed using the Trizol reagent. After dry-
ing the RNA pellet, the RNAeasy kit (Qiagen, Hilden, Germany)
was used for additional puriﬁcation according to the supplier’s
recommendations. The RNA pellet was ﬁnally dissolved in 35 ll
of RNase free water. Synthesis of the cDNA was performed using
the SuperScript III First-Strand Synthesis Super Mix kit (Invitrogen,
Karlsruhe, Germany) according to the manufacture’s protocol. For
the qRT PCR reaction, the TaqMan gene expression assay technol-
ogy and primers were used (Applied Biosystems, Darmstadt,
Germany) according to the supplier’s protocols. Results were
normalized to the endogenous glycerinaldehyd-3-phosphat-
dehydrogenase (GAPDH) control and compared to a reference sam-
ple (untreated HEK 293 cells). Statistical analysis of the data was
performed using the DataAssist v2.0 Software provided (AppliedC
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Fig. 2. Analysis of the PAR1 signal peptide cleavage using marker protein fusions. (A) Sub
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The immunoblot is representative of three independent experiments.Biosystems). For the mRNA degradation assay, HEK 293 cells
(4  106) grown on 60-mm diameter dishes were transiently trans-
fected with plasmid DNA as described above. Twenty-four hours
after transfection, cells were treated with 10 lg/ml Actinomycin
D for various time points. Cells were collected and total RNA extrac-
tion, cDNA synthesis and qRT PCR were performed as described
above.2.10. In vitro transcription
The EasyXpress Insect kit II (Qiagen, Hilden, Germany) was used
for the in vitro transcription according to the manufacture’s proto-
col. To determine transcription efﬁciency, the mRNAwas measured
at 260 nm using the UV Spectrometer NanoDrop™ 2000 (Peqlab,
Erlangen, Germany).2.11. Inositol phosphate accumulation assay
The experiment was carried out with intact transiently
transfected HEK-293 cells as described previously [11]. For PAR1
stimulation, cells were treated with 1 U/ml thrombin.44
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Fig. 3. Analysis of the signal peptide cleavage of the full length PAR1 using N-
terminal FLAG tags preceding the signal peptide. HEK 293 cells were transiently
transfected with the constructs FLAG.PAR1, FLAG.CRF1 and FLAG.V2. (A) ELISA
Assay. Cell surface expression on intact cells was quantiﬁed using a monoclonal
peroxidase-conjugated anti-Flag M2 antibody. Columns represent mean values of
three independent experiments (±SD) (⁄⁄⁄P < 0.001, student’s T-test). (B) Immuno-
ﬂuorescence microscopy using confocal LSM. Intact cells were assessed for the
presence of an uncleaved FLAG epitope using mouse anti-FLAG M2 antibodies and
Cy3-conjugated goat anti-mouse IgG (upper panel). Receptor expression was
veriﬁed by recording the GFP ﬂuorescence signals. (lower panel). Horizontal xy-
scans of representative cells are shown. Scale bar = 10 lm.
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3.1. The PAR1 meets all the necessary criteria for the presence of a
cleavable signal peptide
Cleavable signal peptides of eukaryotic membrane and secre-
tory proteins share characteristic features [12]: a polar and often
charged N-terminal (n) region, a central hydrophobic (h) region
and a polar C-terminal (c) region containing helix-breaking proline
and glycine residues and small uncharged residues at positions-1
and -3 of the cleavage site. Analysis of the N-terminal sequence
of the PAR1 with the ‘‘SignalP3.0’’ bioinformatics software
[13,14] revealed that the N-terminal sequence Met1–Arg23 meets
all criteria for the presence of a functional signal peptide which
is cleaved by the signal peptidases of the ER (Fig. 1B). Signal pep-
tide probability reached a maximal 1.0 value and a cleavage site
seems to be present between residues Ser21 and Ala22.
3.2. The PAR1 possesses a functional and cleaved N-terminal signal
peptide
Length of the parstatin peptide is dependent on whether the
PAR1 possesses a cleavable signal peptide or not. To assess
whether the predicted signal peptide is indeed functional, we fused
the entire PAR1 N tail (Met1–Leu101) with His-tagged GFP (con-
struct PAR1.NT; see Fig. 1A). If the putative signal peptide is func-
tional, the cytosolic GFP protein should be converted to a secreted
protein. As a secretory protein, GFP should appear initially in the
ER and, following transport through the secretory pathway, in
the cell culture medium. However, if the putative signal peptide
is not functional and uncleaved like e.g. the recently described
pseudo signal peptide of the CRF2(a)R [8–10], the construct should
remain in the cytosol. As controls for the secretion experiments, we
used the previously described [8] fusions of the N tails of the CRF1R
(cleaved signal peptide, construct CRF1.NT, Fig. 1A) and the CRF2(a)R
(pseudo signal peptide, construct CRF2(a).NT, Fig. 1A). HEK 293 cells
were transiently transfected with the constructs and the GFP ﬂuo-
rescence signals were localized by LSM and by ﬂuorimetric mea-
surements and immunoblotting. In the case of CRF2(a).NT, the
signals were detected diffusely throughout the cell including the
nucleus demonstrating that these fusions were not targeted to
the ER membrane (Fig. 2A). In contrast, in the case of CRF1.NT
and PAR1.NT, reticular signals were detected demonstrating that
these fusions were able to enter the ER (Fig. 2A; the validity of this
LSM assay has been conﬁrmed previously [8,9]). The reticular sig-
nals also colocalized almost completely with the cotransfected ER
marker protein ECFP-ER (consisting of ECFP fused to a KDEL ER re-
trieval sequence) (Fig. 2B). Consistent with these results, the con-
structs CRF1.NT and PAR1.NT but not CRF2(a).NT could be puriﬁed
via their His-tag from cell culture supernatants and detected by
ﬂuorometric measurements or by immunoblotting (Figs. 2C and D).
Taken together, these results indicate that the PAR1 possesses a
conventional and cleaved signal peptide which is able to direct the
GFP marker protein to the ER and via the secretory pathway ﬁnally
to the cell culture medium.
To conﬁrm these results for the full length PAR1, a FLAG tag was
fused N-terminally to the signal peptide of the PAR1 (Fig. 1A, con-
struct FLAG.PAR1). In addition, the receptor was tagged C-termi-
nally with GFP. If the signal peptide is cleaved, the FLAG tag
should be removed together with the signal peptide in the early
secretory pathway and should no more be detectable at cell surface
receptors. As controls for these experiments, we used the N-termi-
nally FLAG-tagged CRF1R possessing a cleaved signal peptide
(Fig. 1A; construct FLAG.CRF1) and an N-terminally FLAG-tagged
vasopressin V2 receptor (Fig. 1A; construct FLAG.V2) possessingonly a signal anchor sequence. HEK 293 cells were transiently
transfected and receptors were detected on the surface of intact
cells using anti-FLAG antibodies and an ELISA assay (Fig. 3A) or
immunoﬂuorescence microscopy (Fig. 3B). FLAG signals at the cell
surface were detectable in both experiments in the case of the
control construct FLAG.V2 but not for constructs FLAG.CRF1 and
FLAG.PAR1, while all three constructs were readily visible when
monitoring their GFP signals (Fig. 3B, lower panel). These results
demonstrate that the PAR1 possesses a conventional and cleaved
signal peptide and that the signal peptide sequence is conse-
quently not included in the parstatin peptide.
3.3. Deletion of the sequence encoding the signal peptide strongly
decreases the amount of PAR1 mRNA
It was previously shown that signal peptides of GPCRs may
serve different functions in addition to their role in the ER target-
ing/insertion mechanism. Among these are e.g. regulatory effects
on total receptor expression and N tail translocation across the
ER membrane [15]. To analyze the functional signiﬁcance of the
signal peptide of the PAR1, a signal peptide mutant was con-
structed by deleting residues Met1–Ser21 of the C-terminally
GFP-tagged receptor (Fig. 1A; constructs PAR1 and DSP.PAR1,
respectively). Deletion of a signal peptide of a GPCR does normally
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Fig. 4. Analysis of the expression of the full length PAR 1 and its signal peptide mutant DSP.PAR1. (A) SDS–PAGE/immunoblot analysis. Receptors were immunoprecipitated
from transiently transfected HEK 293 cells, digested with PNGaseF to remove all N glycans and detected using a monoclonal anti-GFP antibody and HRP-conjugated anti-
mouse IgG. The immunoreactive protein band with an apparent molecular mass of 70 kDa represents the PAR1. Control = mock-transfected cells. The immunoblot is
representative of three independent experiments. (B) Thrombin-mediated inositol phosphate accumulation in intact HEK 293 cells transiently transfected with the constructs
PAR1 and DSP.PAR1. Cells were treated with thrombin (+) or with vehicle (). Columns represent mean values of three independent experiments each performed in
triplicates (± SD) (⁄⁄⁄P < 0.005, two-way analysis of variance). (C) qRT PCR quantiﬁcation of the mRNA of constructs PAR1/DSP.PAR1 (left panel) and CRF1/DSP.CRF1 (right
panel) in transiently transfected HEK 293 cells. Columns represent fold difference of mRNA expression after normalization to the GAPDH endogenous control compared to the
reference sample (untreated cells) and show mean values of three independent experiments each performed in triplicates (±SD) (⁄⁄⁄P < 0.001; ⁄⁄P < 0.01, student’s T-test). (D)
Degradation of the mRNA of PAR1 and DSP.PAR1 in transiently transfected HEK 293 cells treated for different times with the transcription inhibitor Actinomycin D. Data
points represent the remaining mRNA of GAPDH (left panel) and that of PAR1 and DSP.PAR1 (right panel; normalized to the amount of GAPDH) of three experiments
performed in triplicates (±SD).
2356 D.E. Zampatis et al. / FEBS Letters 586 (2012) 2351–2359not abolish receptor expression since one of the transmembrane
domains usually takes over ER targeting/insertion functions as a
signal anchor sequence. In the case of opsin, for example, it was
shown that ﬁve of the six transmembrane segments studied could
function as a signal anchor sequence [16].
However, when analyzing constructs PAR1 and DSP.PAR1 by
SDS–PAGE/immunoblotting following immunoprecipitation from
transiently transfected HEK 293 cells, we failed to detect signiﬁ-
cant amounts of DSP.PAR1 (Fig. 4A). Moreover, we failed to detect
signiﬁcant GFP ﬂuorescence signals of the signal peptide mutant in
the transiently transfected HEK 293 cells (data not shown) and
DSP.PAR1-mediated inositol phosphate accumulation (Fig. 4B).These results indicate that the signal peptide of the PAR1 surpris-
ingly seems to be necessary for PAR1 expression.
A lack of receptor expression in the case of DSP.PAR1 mutant
could be caused by a failure of the transmembrane domains to
function as signal anchor sequences. On the other hand, the se-
quence encoding the signal peptide might be necessary for efﬁcient
mRNA expression. We thought that it is unlikely that each of the
transmembrane domains is unable to function as a signal anchor
and thus analyzed whether deletion of the sequence encoding
the signal peptide affects mRNA levels. To this end, we ﬁrst per-
formed an in vitro transcription assay using constructs PAR1 and
DSP.PAR1 under the control of the T7 promoter. Photometric
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amounts of mRNA for both constructs (PAR1: 1002 ± 145 ng/ll;
DSP.PAR1: 836 ± 130 ng/ll) indicating that transcription itself is
not signiﬁcantly affected when the sequence encoding the signal
peptide is deleted. Next, we performed qRT-PCR using RNAs iso-
lated from HEK-293 cells transiently transfected with PAR1 and
DSP.PAR1. As a control, we used the C-terminally GFP-tagged full
length CRF1R and its signal peptide mutant (constructs CRF1 and
DSP.CRF1; Fig. 1A). All data were normalized to the endogenous
control of the glycerinaldehyd-3-phosphat-dehydrogenase (GAP-
DH). Substantial amounts of mRNA were detected in the case of
PAR1 but not for DSP.PAR1. In the case of the control constructs
CRF1 and DSP.CRF1, similar amounts of mRNA were detectable
(Fig. 4C), demonstrating that the results were speciﬁc for the PAR1.
When mRNA expression is decreased but transcription itself
not inﬂuenced, the sequence encoding the signal peptide of theFig. 5. Bioinformatic analysis of the putative mRNA secondary structure of PAR1 (upper
signal peptide forms a stem loop structure (arrow and cutaway view) which is missingPAR1 may increase mRNA stability. To address this question,
we performed mRNA decay assays, using Actinomycin D, as an
inhibitor of transcription. Quantiﬁcation of mRNA levels at
various time points using qRT-PCR shows that PAR1 mRNA
levels remained stable for at least 4 h after actinomycin D treat-
ment (Fig. 4D). In contrast, the very low mRNA levels of con-
struct DSP.PAR1 are consistent with a very rapid mRNA
degradation.
To address this question also theoretically, we performed bioin-
formatic analyses of the mRNA secondary structure of PAR1 and
DSP.PAR1 using the program mFold [17] (Fig. 5). The prediction
indicates that the sequence encoding the signal peptide of PAR1
forms a GC-rich long stem loop which is absent in the case of
DSP.PAR1. Formation of such stem loops has indeed been shown
to stabilize mRNA structures consistent with the results above
[18,19].PAR1
ΔSP.PAR1
panel) and DSP.PAR1 (lower panel). In the case of PAR1, the sequence encoding the
in the case of DSP.PAR1. The analysis was performed using the program mFold.
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We show here that the sequence at the N tail of the PAR1 rep-
resents a functional signal peptide which is removed from the
receptor following insertion into the ER membrane. Thus, the pep-
tide which is proteolytically cleaved from the mature receptor at
the plasma membrane following thrombin activation does not con-
tain the residues forming the signal peptide. Most importantly, and
without knowing that the signal peptide of the PAR1 is cleaved off,
it was recently shown that the parstatin fragment represented by
the sequence Met1–Ala26 contains the functional domain of the
peptide [20]. In a rat ischemia–reperfusion injury model, it was
demonstrated the synthetic parstatin (1–26) to be more effective
and potent in the protection of myocardium, compared to full-
sized parstatin (1–41). In the same model the synthetic parstatin
fragment (24–41) is not functional (unpublished data), indicating
that parstatin functions are mediated by the signal peptide alone.
Taking into account that the signal peptide is actually cleaved off
in the early secretory pathway, parstatin effects must originate
from a peptide which is initially embedded in the ER membrane
rather than being released extracellularly. In this case, how can
the cleaved signal peptide then fulﬁll its functions? It is known
for a long time that in some cases, cleaved signal peptides are
not degraded but processed by intramembrane signal peptide pep-
tidases [21,22]. The trimmed peptides may be retranslocated into
the cytosol by an as yet incomplete understood mechanism and
it was proposed that the peptides have physiological functions
following their release [21,22]. In the case of the mouse mammary
tumor virus Rem protein, for example, it was shown recently that
the released peptide is transported into the nucleus and accumu-
lates in nucleoli [23]. Therefore and based on these observations,
it is reasonable to speculate that the cleaved signal peptide of
the PAR1 is also released from the ER membrane. It may translo-
cate to the cytosol or may enter the nucleus in a similar way as de-
scribed for the Rem protein and fulﬁll its functions. Alternatively,
the released signal peptide may have an indirect effect on other
proteins in the cytosol or nucleus. Speciﬁc analytical experiments
are needed to verify the release of the peptide and to further inves-
tigate its fate and biological and physiological role.
In the original experiments leading to the description of the
parstatin effects, the peptide was added to the extracellular side
of the cells [3,5,20]. These results do not conﬂict with the fact that
the relevant peptide obviously does not leave the cells. It is con-
ceivable that the hydrophobic signal peptide may easily enter the
cells when it is added into cell culture medium, either by diffusion
and/or by endocytosis [3].
For the PAR1, we could also show that the sequence encoding
the signal peptide dramatically increases the amount of mRNA,
most likely by facilitating the formation of a stem loop and by pre-
venting rapid RNA degradation. It is already known that such stem
loops may stabilize the secondary structures of mRNAs [24–26]. In
the case of a bacterial protein, a sequence encoding a signal pep-
tide had a similar mRNA-stabilizing effect [27].
In the GPCR protein family, an inﬂuence of a sequence encoding
a signal peptide on mRNA levels is so far unique. In the case of the
ETBR [28], CRF1R [29] and CRF2(a)R [8] deletion of the signal peptide
sequence did not abolish receptor expression. Future studies must
show, whether this function of the signal peptide sequence repre-
sents a more general principle in the GPCR protein family.
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